Panacea Pharmaceuticals, Inc. Presents Data on Targeted Killing of Leukemia Cells By Its Radiolabeled Monoclonal Antibody to the Cancer Biomarker HAAH

Radioimmunotherapy Targeting HAAH in Leukemia is Presented at the American Association for Cancer Research (AACR) Meeting in Washington, DC, April 3, 2017

GAITHERSBURG, Md., March 30, 2017 /PRNewswire/ --

Panacea Pharmaceuticals, Inc. presents a paper regarding targeted killing of leukemia cells by a radiolabeled monoclonal antibody at the annual American Association for Cancer Research (AACR) meeting in Washington DC held April 1-5, 2017. The paper is titled:

“Radioimmunotherapy for Acute Myeloid Leukemia Targeting Human Aspartyl (Asparaginyl) β-Hydroxylase”

The paper demonstrates the use of Panacea’s fully human monoclonal antibody (PAN-622) to human aspartyl (asparaginyl) β-hydroxylase (HAAH) as a radiolabeled therapeutic that kills leukemia cells in vitro.  The PAN-622 was radiolabeled with 213Bi, a short half-life α-emitter.   Eight acute myeloid leukemia cell lines were killed by the 213Bi-PAN-622, but not by a radiolabeled control antibody.  Importantly, normal human leukocytes mixed with the tumor cells were unaffected by the 213Bi-PAN-622.  Thus, radiolabeled HAAH-specific PAN-622 antibody can selectively target and kill leukemia cells.

“We are very excited to report that our radiolabeled fully human monoclonal antibody to the cancer biomarker HAAH specifically targets and kills leukemia cells.  This advance provides evidence for a potential therapeutic application to a devastating cancer and poorly-met healthcare need,” said Hossein Ghanbari, Ph.D., CEO and CSO of Panacea.

 

About Panacea Pharmaceuticals, Inc.

Panacea Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company developing novel biologically targeted cancer therapies and diagnostics for unmet medical needs and is headquartered in Gaithersburg, Md. The company has recently initiated a Phase 1 trial of its PAN-301-1 therapeutic cancer vaccine in prostate cancer patients and has late-nonclinical stage projects in serodiagnosis of cancer, immuno-imaging of cancer, monoclonal antibody-based immunotherapy of cancer and neuroprotection, specifically in prevention of chemotherapy-induced cognitive impairment and peripheral neuropathy.

 

Contact:  Steven Fuller, Panacea Pharmaceuticals, Inc., 240-454-8010, sfuller@panaceapharma.com